Stocksigma LogoStocksigma Logo

Sai Parenterals Reports Nil Deviation in IPO Proceeds Utilization for Sep'26 Quarter

Sai Parenterals confirmed zero deviation or variation in utilizing proceeds from its ₹2,850 million IPO for the quarter ended 30th Sep'26, as monitored by

Sai Parenterals Reports Nil Deviation in IPO Proceeds Utilization for Sep'26 Quarter

Sai Parenterals Ltd · Others (Uncategorized) · 01 Nov 2026, 11:37 pm

Sai Parenterals Reports Nil Deviation in IPO Proceeds Utilization for Sep'26 Quarter Sai Parenterals confirmed zero deviation or variation in utilizing proceeds from its ₹2,850 million IPO for the quarter ended 30th Sep'26, as monitored by India Ratings & Research. Key fund deployments include ₹356.41 million for subsidiary bridge and term loan repayments, ₹330.00 million for working capital, and ₹284.90 million for issue expenses. The company allocated ₹838.34 million (₹100 million utilized) for a 60% equity stake in Saicriti Pharma to construct an injectable facility, alongside ₹150 million utilized for a 60% stake in Prathyak Laboratories.

Original exchange filing (PDF)

More announcements from Sai Parenterals Ltd

All Sai Parenterals Ltd announcements